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WE separately studied the antioxidant  properties of
propofol (PPF), Diprivan® (the commercial form of
PPF) and intralipid (IL) (the vehicle solution of PPF in
Diprivan®)  on  active  oxygen  species  produced  by
phorbol myristate acetate (10–6 M)-stimulated human
polymorphonuclear leukocytes (PMN: 5 3 105 cells/
assay), human endothelial cells (5 3 105 cells/assay)
or cell-free systems (NaOCl or H2O2/peroxidase sys-
tems),  using  luminol  (10–4 M)-enhanced  chemilumi-
nescence (CL). We also studied the protective effects
of  Diprivan®  on  endothelial  cells  submitted  to  an
oxidant stress induced by H2O2/MPO system: cytotox-
icity was assessed by the release of preincorporated
51Cr.  Propofol inhibited the CL produced by  stimu-
lated  PMN  in  a  dose  dependent  manner  (until  5  3
10–5 M,  a  clinically  relevant  concentration),  while
Diprivan®  and  IL  were  not  dose-dependent  inhibi-
tors. The CL produced by endothelial cells was dose-
dependently  inhibited  by  Diprivan®  and  PPF,  and
weakly  by  IL  (not  dose-dependent).  In  cell  free
systems,  dose-dependent  inhibitions  were  obtained
for  the  three  products  with  a  lower  effect  for  IL.
Diprivan®  efficaciously  protected  endothelial  cells
submitted to an oxidant stress, while IL was ineffec-
tive.  By  HPLC,  we  demonstrated  that  PPF  was  not
incorporated  into the cells.  The drug  thus acted by
scavenging the active oxygen species released in the
extracellular medium. IL acted in the same manner,
but was a less powerful antioxidant.
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Introduction
Active  oxygen  species  (AOS)  are  involved  in  tissue
injury  associated  with  many  acute  inflammatory
processes  including  sepsis,  acute  lung  injury  and
severe  trauma.
1,2 The  liposoluble  anaesthetic  drug,
propofol (2,6-diisopropylphenol) (PPF), shares a sim-
ilar  structure  with  phenolic  antioxidants  like  the
endogenous a -tocopherol (vitamin E) which has been
shown to protect cellular membranes against lipoper-
oxidation processes induced by AOS.
3 PPF has been
demonstrated to inhibit the in vitro lipoperoxidation
of  microsomes  and  mitochondria  isolated  from  rat
liver, at clinically relevant doses,
4,5 and in a similar way
as a -tocopherol.
6 In addition, it has been reported that
rats  receiving  PPF  have  hepatic  microsomes  more
resistant  to  lipoperoxidation.
7 By  its  antioxidant
effects,  PPF  stabilizes  the  rat  liver  mitochondrial
membranes exposed to an oxidative stress, inhibiting
the Ca
2+ induced permeabilization of mitochondria.
8
PPF has also been demonstrated to protect erythrocyte
membranes against free radicals produced by thermic
decomposition  of an  azo-compound
9 and  to inhibit
hyaluronan  depolymerization  by  AOS  produced  by
xanthine oxidase activity.
10 PPF could also attenuate
ischaemia  reperfusion  injury.
11,12 Finally,  we  have
shown that  PPF could inhibit  the peroxidation of a
lipidic  emulsion  induced  by  ferryl,  oxoferryl  or
hydroxyl radicals, and that its inhibiting effect was as
efficient as that of a -tocopherol.
13
The  effects  of  clinically  relevant  doses  of  Dipri-
van®, the commercial form of PPF, on AOS produced
by stimulated polymorphonuclear neutrophils (PMN),
have  been  investigated  by  assessing  different  cell
functions such as deformability, chemotactism, respi-
ratory  burst,  phagocytosis  and  bactericidal  activity.
These  studies  yielded  contradictory  results.  Dipri-
van® has been reported to inhibit the cell mobility,
14
the  PMN  chemotactically  induced  polarization,
15,16
the PMN hydrogen peroxide (H2O2) production,
17,18
as  well  as  the  cell  capacity  to  phagocyte  and  kill
bacteria such as Staphylococcus aureus and Escher-
ichia  coli.
19 Chemiluminescence  studies  performed
on  isolated  PMN  stimulated  by  N-formyl  methionyl
phenylalanine  (FMLP)  or  by  zymosan  reported  that
Diprivan® inhibited the production of the AOS.
20–23
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did not modify the respiratory burst and the phagocy-
tosis activity of PMN.
24,25
In  fact,  intralipid  (IL),  the  solvent  of  PPF  in
Diprivan®,  has  been  demonstrated  to  inhibit  the
mobility, the respiratory burst and the phagocytosis
capacity  of  PMN.
14,18,19,26 Therefore,  it  may  be
important  to  assess  separately  the  effects  of  Dipri-
van®, IL and PPF.
The  present  study  was  designed  to  investigate
separately  the  effects  of  PPF  (diluted  in  an  appro-
priate medium that did not interfere with the action
of PPF), Diprivan® and IL on the stimulation of PMN,
and on the production of H2O2 by cultured endothe-
lial cells, using luminol-enhanced chemiluminescence
(CL).
27 Cell-free  systems  where  CL  resulted  from
sodium hypochlorite (NaOCl) or from the reaction of
H2O2 with peroxidases were also studied. In addition,
the effect of Diprivan® on cultured human endothe-
lial  cells  submitted  to  an  oxidant  stress  was  also
studied, to examine the potential interest of this agent
in  clinical  situations  characterized  by  an  excessive
PMN stimulation leading to an endothelium oxidative
stress.
1,2 Using  HPLC  technique,  we  quantified  the
incorporation of the drug into the PMN or endothelial
cells to establish the extra- or intracellular mechanism
of action of PPF.
Methods
Materials
Sodium, potassium, ammonium, calcium and magne-
sium  salts,  glucose,  H2O2,  NaOCl,  diethylenegly-
colmonoethylether  (carbitol),  thymol,  cyclohexane,
acetonitrile,  trifluoroacetic  acid  (HPLC  grade),  and
the  HPLC  column  (Nucleosil  RP-18,  5 m m  particle
size,  125  3 5 mm)  were  purchased  from  Merck
(Germany). 3-Aminophtalhydrazide (luminol), trypan
blue,  human  serum,  heparin,  gelatine,  phorbol-
12-myristate-13-acetate  (PMA)  were  from  Sigma
Aldrich (Belgium).  Fetal  calf  serum, M199  Medium,
antibiotics,  culture  dishes  and  Polymorphprep
TM
were  from  Gibco  BRL  (Belgium).  Endothelial  cell
growth  factor  (ECGF),  dispase,  horseradish  perox-
idase  (HRP)  were  from  Boehringer-Mannheim  (Bel-
gium); 
51Chromium  (
51Cr)  (sodium  chromate)  was
from Amersham (Belgium).
Propofol  and  Diprivan®  were  gifts  from  Zeneca
(Belgium). Intralipid was from Kabi  Pharmacia (Bel-
gium). Human myeloperoxidase (MPO) was purified
in our laboratory as previously described.
28
Phosphate-buffered  saline  (PBS)  was:  Na2HPO4
1.15 g/l;  KH2PO4 0.2 g/l;  KCl  0.2 g/l;  NaCl  8 g/l.
Hanks’ balanced salt solution (HBSS) was: Na2HPO4
0.48 g/l;  KH2PO4 0.06 g/l;  NaHCO3 0.35 g/l;  KCl
0.4 g/l; NaCl 8 g/l; MgCl2.6H2O 0.1 g/l; MgSO4.7H2O
0.1 g/l; CaCl2.2H2O 0.185 g/l; glucose 1g/l.
Isolation of PMN
Human PMN were isolated from buffy coats of healthy
donors (Blood Transfusion Centre, University Hospital
of  Li` ege)  by  density  gradient  centrifugation.  Buffy
coats were added with 1 volume of Polymorphprep
TM
and  centrifuged  at  room  temperature  (500  3 g,
30 min). The supernatant was diluted with 0.5 volume
of 0.9% NaCl and centrifuged (1000 g 3 g, 20 min).
The  collected  cells  were  washed  with  a  hypotonic
solution (155 mM NH4Cl, 170 mM Tris-HCl, pH 7.4) to
lyse remaining erythrocytes. After centrifugation (800
3 g, 15 min),  the collected cells  were washed  and
adjusted  to  10  3 10
6 cells/ml  in  NaCl  0.9%  (stock
solution). Viable cells in this preparation, assessed by
the exclusion of trypan blue, were higher than 98%.
Human endothelial cell culture
Endothelial cells were isolated from human umbilical
vein (HUVEC) by dispase treatment according to Jaffe
et al.
29 HUVEC were cultured on 0.2% gelatine coated
dishes in M199 medium supplemented with 10% heat-
inactivated  fetal  calf  serum,  5%  heat-inactivated
human  serum,  penicillin  (100 U/ml),  streptomycin
(100 m g/ml),  heparin  (90m g/ml)  and  ECGF
(20 m g/ml). The cells were used at passage 2.
Drug solutions
The commercial form of PPF (Diprivan® : PPF 10 mg/
ml)  is  formulated  in  intralipid  (IL),  a  lipid  vehicle
emulsion (10% soya bean emulsion, egg phosphatides
and glycerol). Tests were performed separately with
PPF,  Diprivan®  and  IL.  Diprivan®  or  equivalent
volumes of IL were added to the reaction milieu and
compared  with  results  obtained  in  the  absence  of
Diprivan® and IL (control value taken as 100%). Before
addition to the test tube, pure PPF was dissolved in
carbitol to obtain  the appropriate concentrations. A
volume of 5 m l of the drug solution was always added
to a final volume of 0.5 ml of PBS. Control tests were
performed with 5m l of carbitol alone, and the resulting
CL value was taken as 100% (control value).
Chemiluminescence assays
Luminol  enhanced  chemiluminescence  (CL)  was
measured in a Bio-Orbit 1251 Luminometer. All the CL
assays were performed in a final volume of 0.5 ml PBS.
The CL values were recorded over time and comput-
erized.  Maximal  light  emission  (peak  CL)  and  total
emitted  light  (area  under  the  time  curve)  were
considered. Results were expressed as the percentage
inhibition of the control value.
PMN CL assay
CL was measured at 37°C in the presence of 5 3 10
5
PMN (50m l of the stock solution), luminol (10
–4 M)
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PPF dissolved in carbitol. The reaction was started by
addition of PMA (10
–6 M). The CL was recorded for
10 min.  The  results  represent  means  ±  SD  of  five
independent  assays  performed  with  PMN  isolated
from five different buffy coats.
HUVEC CL assay
Adherent HUVEC were washed three times with PBS
and gently scraped with a rubber policeman into PBS.
After centrifugation, the cells were suspended in PBS
(5 3 10
6 cells/ml). The assay was performed at 37°C,
in a final volume of 0.5 ml of PBS containing 100 m l of
the cell suspension (final number of cells: 5 3 10
5),
luminol  (10
–4 M)  and  horseradish peroxidase  (HRP)
(2.5 U/ml). The  CL  was  measured  for  20min.  The
assays were repeated three times.
NaOCl CL assay
The assay was done in the presence of luminol (5 3
10
–7 M).  NaOCl  (10
–5 M  final  concentration)  was
injected and  the peak value of CL was immediately
recorded. Each assay was done in triplicate and the
experiment was repeated three times (n=9).
H2O2/peroxidase CL assay
Two peroxidases were tested: MPO (1.4 m g/ml) and
HRP  (0.2 U/ml).  The  assay  was  performed  in  the
presence  of  luminol  (10
–4 M).  H2O2 at  the  final
concentration  of 10
–6 M or  2  3 10
–7 M for MPO or
HRP respectively, was injected and the peak value of
CL was recorded. Each assay was done in triplicate for
MPO and nine times for HRP.
Cytotoxicity assay on HUVEC
Cytotoxicity was assessed by measuring the release of
previously incorporated 
51Cr. Confluent HUVEC in six
multiwell plates were labelled overnight by 10 m Ci/ml
51Cr  added  in  the  culture  medium.  HUVEC  were
washed in HBSS to remove unincorporated 
51Cr, and
then  incubated  for  1 h  in  1 ml  of  HBSS  containing
MPO (5 m g), with or without addition of Diprivan® or
IL. H2O2 (10
–4 M) was added to initiate the enzymatic
activity of MPO. After a further 2 h incubation at 37°C,
the supernatants were collected and  the cells were
washed  three  times  with  HBSS.  Supernatant  and
washings were pooled and 
51Cr release was quantified
by g counting. Cells were lysed in NaOH (1 N) and the
intracellular 
51Cr was counted. The percentage of 
51Cr
release  was  calculated  for  each  test  condition.  An
index of cytotoxicity (IC) was calculated as described
elsewhere.
28
The  protective  effect  of  Diprivan®  against  the
oxidative stress was calculated as follows




where ICDiprivan® and ICstress were respectively the IC
obtained  in  the  presence  or  in  the  absence  of
Diprivan®.  The  experiment  was  repeated  with
HUVEC isolated from two different donors (n=9).
HPLC analysis of PPF incorporation into the
cells
PMN or HUVEC (5 3 10
5 cells) were incubated with
Diprivan® or PPF (10
–4 M or 10
–3 M) for 1 h at 37°C in
1 ml of HBSS. After incubation, the supernatant  and
the cells were separated and  PPF  was extracted by
cyclohexane  after  addition  of  thymol  as  internal
standard.
30 The solvent was evaporated to dryness at
ambient temperature under nitrogen. The residue was
dissolved  in  HPLC  mobile  phase,  acetonitrile/H2O/
trifluoroacetic  acid  (600:400:1  by  vol.),  and  sub-
mitted to HPLC analysis  on  RP-18  column  with UV
detection. The experiment was repeated twice.
Statistical analysis
All  the  results  were  expressed  in  percentage  of
control  and  presented  as  mean  values  with  the
standard deviation. Statistical analysis was performed
using  the  Student’s  t-test.  P<  0.05  was  considered
statistically  significant.  Dose–response  curves  were
fitted by regression models (Pearson’s test) using PPF
concentrations in logarithmic scale.
Results
Effect of Diprivan®, IL and PPF on the CL of
activated PMN
The  effects  of  different  concentrations  of  IL  and
Diprivan® on the CL of activated PMN are shown in
Table  1. The  percentage  of  inhibition  was  variable,
depending  on  the  different  preparations  of  PMN.
However in all cases, IL alone yielded an inhibitory
effect  which  did  not  differ  significantly  from  the
effect of Diprivan®.
Pure  PPF  inhibited  the  CL  of  PMN  in  a  dose-
dependent manner (Fig. 1), in the range of 5 3 10
–5 M
(37.3 ± 6.3 percentage of inhibition) to 10
–3 M (93.5
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Table 1. Effects of Diprivan® on the chemiluminescence (CL)
of 10–6MPMA stimulated PMN: comparison with the effects
of intralipid (IL), the vehicle solution of PPF in Diprivan®
PMN
preparation
%  of inhibition of CL Diprivan®/IL
volume in m L
0.09 0.9 2.7 9
1 0/22 84/73 97/96 98/95
2 0/0 39/35 52/47 53/47
3 25/47 24/19 68/61 71/57
4 – 76/75 70/73 84/82± 2.1 percentage of inhibition). The concentration of
5  3 10
–5 M  propofol  corresponds  to  a  clinically
relevant concentration. A significant linear correlation
was obtained between the inhibition of CL and the
PPF (logarithmic scale) concentrations (r
2=0.930).
Effects of Diprivan®, IL and PPF on the CL of
HUVEC
IL  and  Diprivan®  inhibited  the  HUVEC  response,
Diprivan® yelding a higher effect than IL (Fig. 2). For
Diprivan®,  inhibition  was  observed  from  10
–6 M
(25.8 ± 6.8 percentage of inhibition) to 10
–4 M (95.6
±  1.1  percentage  of  inhibition).  A  saturation  effect
was obtained with IL: inhibition of CL rapidly reached
a plateau at 30.9 ± 0.2 percentage of inhibition. Pure
PPF inhibited the CL of HUVEC in a dose-dependent
manner (Fig. 2) in the range of 2.5 3 10
–6 M to 10
–4 M
(respectively 28.4 ± 5.8 and 96.0 ± 1.8 percentage of
inhibition).  For  pure  PPF  and  Diprivan®  a  linear
correlation was found between inhibition of CL and
the drug concentration (respectively r
2 = 0.943 and
0.955).  The  PPF  concentrations  required  for  CL
inhibition  of HUVEC were lower than for CL inhibi-
tion  of  PMN,  but  PMN  produced  more  AOS  than
endothelial cells: the CL of PMN was 40 times that of
HUVEC.
Effects of Diprivan®, IL and PPF on the CL of
NaOCl
The  CL  resulting  from  NaOCl  was  inhibited  by
Diprivan® and IL, in a dose-dependent manner (linear
correlations with respectively r
2 = 0.953 and 0.940)
(Fig.  3)  but  Diprivan®  yielded  the  most  inhibiting
effect.  A  significant  inhibition  (35.8  ±  1.0%)  was
already obtained with 3 3 10
–6 M of Diprivan®, while
IL was ineffective.
For pure PPF dissolved in carbitol the inhibition of
CL was already significant for a PPF concentration of
5 3 10
–6 M (25.9 ± 6.7 percentage of inhibition) (Fig.
3). A linear correlation was obtained between inhibi-
tion of CL and the PPF  (logarithmic scale) concentra-
tions (r
2= 0.914).
Effects of Diprivan®, IL and PPF on the CL of
H2O2/peroxidase systems
H2O2/HRP
The effects of Diprivan®, IL and pure PPF on the CL
of  the  H2O2/HRP  system  are  presented  in  Fig.  4A.
Inhibition  of the CL was again observed with Dipri-
van®  and  IL  with  a  more  pronounced  effect  for
Diprivan® (inhibition in the range of 10
–6 M to 10
–4 M
of Diprivan® with respectively 20.0 ± 0.8 and 98.6 ±
0.1 percentage of inhibition). The inhibitiory effect of
pure PPF dissolved in carbitol was also observed: 11.7
± 0.3 percentage of inhibition for 3 3 10
–6 M to 92.7
± 0.3 percentage of inhibition for 3 3 10
–5 M. Linear
correlations were obtained between inhibition of CL
M. Mathy-Hartert et al.
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FIG. 1. Dose-dependent inhibition (±SD) of the CL of stimu-
lated PMN by PPF (n=5).
FIG. 2. Inhibition (±SD) of the CL of endothelial cells by pure
PPF dissolved in carbitol (s s ). Diprivan® (h · h ) or
intralipid (IL) (d d ) (n=9).
FIG. 3.  Inhibition  (±SD)  of  the CL of NaOCl by  pure  PPF
dissolved  in  carbitol  (s s ),  Diprivan®  (h · h )  or
intralipid (IL) (d d ) (n=9).and  the drug concentration  (logarithmic scale) (r
2=
0.96, 0.98 and 0.92 respectively for Diprivan®, IL and
pure PPF).
H2O2/MPO
The effects of Diprivan®, IL and pure PPF on the CL
of H2O2/MPO system are presented in Fig. 4B. Linear
dose-dependent  inhibition  of  the  CL  was  observed
(r
2=0.96, 0.87 and 0.98 respectively for Diprivan®, IL
and  pure  PPF).  The  inhibiting  effect  was  already
significant  at  3  3 10
–6 M  PPF  dissolved  in  carbitol
(32.1 ± 1.2 percentage of inhibition) and 3 3 10
–6 M
Diprivan®  (24.9  ±  3.9  percentage  of  inhibition),
while IL was ineffective.




– system  induced  an  oxidative
stress  on  HUVEC  (IC=32.8  ±  7.6%).  Diprivan®
exerted  a  protective,  dose-dependent  effect
(r
2=0.783) on HUVEC against this oxidative stress, in
the range of 0.3  to 3 3 10
–4 M PPF  concentrations
(respectively 27.8 ± 6.3 and 97.6 ± 5.8 percentage of
protection) (Fig. 5). No protection was observed with
IL alone. Because of a cytotoxic effect of carbitol after
3 h  incubation,  PPF  dissolved  in  carbitol  was  not
tested in this experiment.
PPF incorporation into PMN and HUVEC
Small amounts of PPF were incorporated into PMN.
PMN  incubated  with  10
–3 M  Diprivan®  or  PPF  in
carbitol incorporated respectively 2.5% and 5.1% of
the drug; for 10
–4 M Diprivan® or PPF in carbitol, we
found respectively 0% or 2.2% of incorporation. No
PPF incorporation was found into HUVEC.
Discussion
The present study was designed to investigate sepa-
rately the effects of pure PPF, IL and Diprivan® on the
production of AOS by PMN and endothelial cells, and
on cultured human endothelial cells submitted to an
oxidant stress. First, the study emphasized the dose-
dependent inhibiting effect of PPF (diluted in carbi-
tol) on the luminol-enhanced CL produced by stimu-
lated neutrophils and endothelial cells. In addition, it
showed the capacity of PPF and Diprivan® to inhibit
the chemiluminescence of NaOCl and of the H2O2/
peroxidase systems. These effects could be attributed
to the non-hypnotic properties of Diprivan®. Accord-
ing to other results of this study, IL, the emulsified
vehicle solution of PPF in Diprivan®, yielded a lower,
but  significant  and  dose-dependent  inhibiting effect
on the CL of HUVEC and cell-free systems. The HPLC
study showed that PPF did not enter the cells. The CL
inhibition  could  thus  be  attributed  to a  scavenging
action on AOS, and  not to an inhibition of the AOS
production by the cells.
Considering the production  of AOS  by stimulated
PMN, the inhibiting effects of Diprivan® were varia-
ble  depending  on  cell  batches  and  dose-dependent
relationship  could  not  be  clearly  established.  The
inhibiting  effect  of  IL  tested  separately  did  not
significantly  differ  from  that  of  Diprivan®.  This
inhibitory effect of IL is quite difficult to explain. It
might  be  due  to  the  physical  properties  of  the
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FIG. 4. Inhibition  (±SD) of the CL of the H2O2/peroxidase
system (above: H2O2/HRP; below: H2O2/MPO) by pure PPF
dissolved  in  carbitol  (s s ),  Diprivan®  (h · h )  or
intralipid (IL) (d d ) (n=9 for H2O2/HRP; n=3 for H2O2/
MPO).
FIG. 5. Dose-dependent protection (±SD) of endothelial cells
by Diprivan® against oxidant stress (n=9).emulsion  producing  a  nephelometric  effect  in  the
reaction vessel during the CL measurement; however,
this is unlikely as the volumes of IL used in our assays
were too small to obtain this nephelometric effect. A
chemical reaction of IL with the AOS is more likely: IL
contains  mainly  triglycerides  with  saturated  and
unsaturated fatty acids. The unsaturated lipids could
act as AOS scavengers. IL could also act directly on
cell  membranes,  and  induce  structure  alterations
leading  to  a  decrease  of  the  AOS  release  in  the
extracellular  medium  with  a  decrease  of  the  CL
response.  Inhibitory  effects  of  IL  on  the  functions
(chemotaxis,  phagocytosis,  bactericidal  activity,
superoxide  anion  generation)  of  PMN  were  pre-
viously reported and  often  attributed to changes of
the structure of the cell membranes.
14,15,18 Propofol
alone (diluted in a non interfering solvant) had dose-
dependent  inhibiting  effect  on  the  CL  response  of
PMN and endothelial cells, and was active at clinically
relevant concentrations (range: 10
–5 to 10
–4 M).
These new results confirmed our first observations
of an in vitro antilipoperoxidant effect of pure PPF
13
and were in agreement with the data collected from
the  literature,  which  demonstrated  the  in  vitro
antioxidant and antiradical properties of PPF in cell-
free  systems  of  erythrocyte  membrane,  microsome
and  mitochondria  membrane  lipoperoxidation.
4–9
The effects of PPF on PMN functions like chemotact-
ism,  respiratory  burst  and  phagocytosis  have  been
extensively investigated,
15–19 but few data using the
chemiluminescence  technique  are  available.  Four
studies
20–23 reported  the  inhibiting  effect  of  Dipri-
van®  on  the  CL  produced  by  N-formyl-methionyl-
leucyl-phenylalanine  (FMLP)  or  zymosan-stimulated
PMN and on FMLP stimulated PMN after priming with
TNF-a . From these studies, it appeared that IL was less
active  than  Diprivan®.
20–22 Regarding  the  different
AOS  producing  systems  in  our  study,  the  dose-
dependent  inhibiting  effect  of  PPF  dissolved  in
carbitol differed from that observed with Diprivan®.
In  the majority  of the experimental  conditions, the
effects of Diprivan® at low concentrations reflected
additive effects of IL and pure PPF . The percentage of
inhibition of Diprivan® at 10 and 30 m M PPF on the
CL of NaOCl was equivalent to the sum of inhibition
values measured with IL and PPF dissolved in carbitol.
In the same way, considering the H2O2/ HRP system,
the CL inhibiting effect of 10 m M Diprivan® was the
sum of the inhibition  of IL and  of PPF dissolved in
carbitol.  In  contrast,  the  CL  assays  performed  on
stimulated  endothelial  cells  did  not  yield  similar
results. In  these conditions,  the  inhibiting  effect of
increasing  concentrations  of  IL  quickly  reached  a
plateau. This plateau effect reflects a lesser scaveng-
ing activity of IL compared with PPF and a difference
in AOS production by HUVEC and PMN. Hence, it is
unlikely  that  HOCl  could  be  produced  by  HUVEC
given the absence of MPO into these cells.
The  experimental  conditions  using  different  CL
producing  systems provide us with  a  partial  under-
standing of the mechanism of action of pure PPF on
the AOS. In fact, the CL of stimulated PMN reflects the
global production of AOS including superoxide anion
(O2
d ) and  its derivative hydrogen  peroxide (H2O2),
hypochlorous  acid  (HOCl)  produced  by  the  enzy-
matic activity of MPO, NO
d , peroxynitrite (resulting
from the reaction between O2
d and NO
d ) and other
excited  oxygen  species  such  as singlet  oxygen  and
hydroxyl radical.
31 PPF may exert its inhibiting effect
on CL of PMN at different levels. It has already been
shown  to  neutralize hydroxyl  radical.
13 From  other
studies,  it  appeared  that  PPF  could  affect  the AOS
produced by the activity of xanthine oxidase,
10 and
restore the relaxing effect of aortic rings impaired by
AOS.
32 Recently,  PPF  was  demonstrated  to  be  a
scavenger  of  peroxynitrite.
33,34 The  observations
reported here indicate that PPF also may act both on
HOCl  and  H2O2,  or  directly  affect  the  activity  of
peroxidases. Its mechanisms of action on stimulated
endothelial cells are still difficult to accurately define;
indeed, these cells are able to produce O2
d and H2O2
from intracellular xanthine oxidase, as well as perox-
ynitrite from NO
d .
Finally,  the  inhibiting  property  of  PPF  might  be
considered as an  unwanted side effect of the drug,
since  it  could  reduce  the  phagocytosis  activity  of
PMN.  However  in  the  experimental  conditions  of
the  present  study,  the  PMN  stimulation  by  PMA
resulted  in  a  degranulation  process  and  the  release
of  active  enzymes  and  AOS  outside  the  cells,  as
demonstrated by the measurement of active granulo-
cytic enzymes (MPO, elastase) in the reaction milieu.
Should  the  scavenging  activity  of  PPF  be  directed
only  against  the  excited  oxygen  species  released
outside the cells, PPF will be protective against the
cellular and tissue destruction induced by an oxida-
tive  stress. Such  a  stress could  be produced partic-
ularly  by  HOCl,  a  potent  oxidant  molecule capable
of  reaching  areas  quite  distant  from  its  production
site.  By  chromatographic  analysis  (HPLC),  we  dem-
onstrated  that  PPF  does  not  enter the cell  (neither
PMN  nor  endothelial  cells)  and  therefore  does  not
act  intracellularly.  Moreover,  we  also  demonstrated
that Diprivan® protects endothelial  cells against an
oxidative  stress  while  intralipid  alone  was  without
effect,  and  we  recently  reported  an  increased  anti-
oxidant capacity of plasma in patients anaesthetized
with  PPF.
35 These  results  could  suggest  a  potential
benefit of PPF in clinical situations characterized by
an  excessive  PMN  activation  in  the  absence  of
cytotoxic compounds resulting from the reaction of
this agent  with AOS.
In  conclusion,  using the luminol-enhanced chem-
iluminescence technique, we demonstrated that the
inhibiting property of PPF on the production of AOS
in  different  experimental  conditions  is  also  shared
M. Mathy-Hartert et al.
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which  is the vehicle solution  of  PPF  in  Diprivan®.
Both the active principle and the solvent have dose-
dependent effects which are additive at low concen-
trations. Diprivan® was also protectvie for endothe-
lial cells submitted to an oxidant stress. As PPF did not
enter the cells, the drug would act by scavenging the
active  oxygen  species  released  in  the  extracellular
medium. IL would act in the same manner, but with a
lower antioxidant capacity.
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